NASDAQ: MGXMetagenomi Inc Stock
$1.52+0.04 (+2.7%)
Updated Apr 17, 2025
MGX Price
$1.52
Fair Value Price
N/A
Market Cap
$56.82M
52 Week Low
$1.23
52 Week High
$8.40
P/E
-0.64x
P/B
0.24x
P/S
2.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$52.30M
Earnings
-$78.06M
Gross Margin
100%
Operating Margin
-159.81%
Profit Margin
-149.3%
Debt to Equity
0.38
Operating Cash Flow
-$109M
Beta
0.72
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MGX Overview
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MGX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MGX
Ranked#229 of 463
Ranked#229 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important MGX news, forecast changes, insider trades & much more!
MGX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MGX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MGX is good value based on its book value relative to its share price (0.24x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
MGX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MGX due diligence checks available for Premium users.
Valuation
MGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.64x
Industry
-177.72x
Market
27.98x
MGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.24x
Industry
4.05x
MGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MGX's financial health
Profit margin
Revenue
$9.6M
Net Income
-$23.4M
Profit Margin
-243.4%
MGX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MGX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$324.6M
Liabilities
$89.7M
Debt to equity
0.38
MGX's short-term assets ($257.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGX's short-term assets ($257.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.3M
Investing
$28.5M
Financing
$0.0
MGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MGX vs Biotech Stocks
Metagenomi Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.